Ovid Therapeutics Reports Q1 Results, Extends Cash Runway to 2029, and Advances Multiple Pipeline Programs

summarizeSummary

Ovid Therapeutics announced Q1 2026 financial results, confirming a strong cash position and an extended financial runway into 2029, alongside significant advancements in its OV329 and OV4071 clinical pipeline programs.

check_boxKey Events

• Extended Financial Runway

  Cash, cash equivalents, and marketable securities totaled $165.6 million as of March 31, 2026, with an additional $27.3 million received in April from Series A warrant exercises. This, combined with a $60 million PIPE financing, extends the company's financial runway into 2029.

• OV4071 Phase 1 Dosing Initiated

  The first participant was dosed in a Phase 1 study for OV4071, an oral KCC2 direct activator, in May 2026, targeting conditions like Parkinson's disease psychosis and schizophrenia.

• OV329 Pipeline Expansion

  The OV329 program is expanding into new pediatric indications for tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), with Phase 2 studies for treatment-resistant epilepsies planned for Q2 2026.

• Favorable OV329 Safety Data

  Higher dose cohorts (7mg and 9mg) of OV329 demonstrated a favorable safety and tolerability profile in clinical studies, supporting continued clinical development.

auto_awesomeAnalysis

Ovid Therapeutics reported its first-quarter 2026 financial results, highlighting a strengthened balance sheet with cash and equivalents totaling $165.6 million as of March 31, 2026, further bolstered by an additional $27.3 million received in April from warrant exercises. This, combined with a $60 million PIPE financing, extends the company's financial runway into 2029, significantly de-risking its operations. The company also announced substantial progress across its pipeline, including dosing the first participant in a Phase 1 study for OV4071 and expanding the OV329 program into new pediatric indications for tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), with favorable safety data for higher doses of OV329.